Patent filing marks another milestone in
becoming a world leader in pain management
LAS
VEGAS, June 28, 2023 /PRNewswire/ -- JanOne Inc.
(Nasdaq: JAN), a biopharmaceutical company that is developing
multiple drugs to treat chronic diseases like Peripheral Artery
Disease (PAD) and Complex Regional Pain Syndrome (CRPS), has just
filed an international patent application for methods of using low
dose naltrexone to treat chronic pain.
Dr. Amol Soin, the chief medical
officer and inventor mentioned, "This patent filing, should it
issue, will bolster our plans to help treat patients suffering from
complex regional pain syndrome across the globe, using our novel
formulation and dosing strategy that we feel will be advantageous
with our drug candidate, Jan123."
JanOne is developing Jan123 (a novel formulation of low dose
naltrexone) to treat CRPS, an orphan disease with no current
FDA-approved treatments. CRPS leaves patients in debilitating pain
and suffering and, as a result, oftentimes patients resort to
opioid pain medications. "We believe that Jan123 may offer hope to
patients with CRPS and look forward to conducting a large-scale,
clinical trial to facilitate FDA approval", noted Dr. Soin.
"It appears this debilitating condition is now getting the
attention it deserves from the media with the premier of the
Netflix documentary, entitled TAKE CARE OF MAYA." Dr. Soin
concluded.
"This international patent application is part of our strategy
to help patients around the world who are suffering from this
debilitating disease. If this issues, it should bolster our already
robust intellectual property portfolio", stated Mr. Tony Isaac the CEO of JanOne.
Forward Looking Statements
This press release contains statements that are forward-looking
statements as defined within the Private Securities Litigation
Reform Act of 1995, including, but not limited to, statements
relating to the statements that Jan101 will treat PAD, that Jan123
will treat CRPS, the timing of the commencement of further clinical
trials, that the FDA will permit approval through a 505(b)(2)
pathway for Jan123, that upon approval Jan101 will immediately
disrupt the PAD market, and other statements, including words such
as "continue", "expect", "intend", "will", "hope" "should",
"would", "may", "potential" and other similar expressions.
Such statements reflect JanOne's current view with respect to
future events, are subject to risks and uncertainties, and are
necessarily based upon a number of estimates and assumptions that,
while considered reasonable by JanOne, are inherently subject to
significant business, economic, competitive, political and social
uncertainties and contingencies. Many factors could cause JanOne's
actual results, performance or achievements to be materially
different from any future results, performance or achievements
described in this press release. Such factors could include, among
others, those detailed in the Company's periodic reports filed with
the Securities and Exchange Commission (the "SEC").
Should one or more of these risks or uncertainties materialize,
or should the assumptions set out in the section entitled "Risk
Factors" in JanOne's filings with the SEC underlying those
forward-looking statements prove incorrect, actual results may vary
materially from those described herein. These forward-looking
statements are made as of the date of this press release and JanOne
does not intend, and does not assume any obligation, to update
these forward-looking statements, except as required by law. JanOne
cannot assure that such statements will prove to be accurate as
actual results and future events could differ materially from those
anticipated in such statements. Individuals are cautioned that
forward-looking statements are not guarantees of future performance
and accordingly investors are cautioned not to put undue reliance
on forward-looking statements due to the inherent uncertainty
therein.
About JanOne Inc.
JanOne is a unique Nasdaq-listed company offering innovative,
actionable solutions that it believes can help end the opioid
crisis. JanOne is dedicated to funding resources toward innovation,
technology and education to find a key resolution to the national
opioid epidemic, which is one of the deadliest and most widespread
in the nation's history. Its drugs in the clinical trial pipeline
have shown promise for their innovative targeting of the causes of
pain as a strategic option for physicians averse to exposing
patients to addictive opioids.
Please visit www.janone.com for additional information.
Media Contact
Investor Relations
IR@janone.com
1-800-400-2247
View original content to download
multimedia:https://www.prnewswire.com/news-releases/janone-files-international-patent-application-for-methods-of-using-low-dose-naltrexone-to-treat-chronic-pain-301865422.html
SOURCE JanOne Inc.